Saroja Pharma Industries India Ltd
Incorporated in 2023, Saroja Pharma Ltd is mainly in the business of trading Thionyl Chloride chemical and pharmaceutical intermeddles, etc.[1]
- Market Cap ₹ 17.3 Cr.
- Current Price ₹ 43.0
- High / Low ₹ 62.0 / 34.0
- Stock P/E 13.6
- Book Value ₹ 40.4
- Dividend Yield 0.00 %
- ROCE 12.6 %
- ROE 6.79 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 1.06 times its book value
- Company's working capital requirements have reduced from 39.6 days to 29.9 days
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 10.0% over last 3 years.
- Company has high debtors of 181 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Commodities Chemicals Chemicals & Petrochemicals Specialty Chemicals
Half Yearly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|
| 36.66 | 55.63 | 50.19 | 40.67 | 53.73 | 73.87 | |
| 35.36 | 53.53 | 47.47 | 38.11 | 50.95 | 70.73 | |
| Operating Profit | 1.30 | 2.10 | 2.72 | 2.56 | 2.78 | 3.14 |
| OPM % | 3.55% | 3.77% | 5.42% | 6.29% | 5.17% | 4.25% |
| 0.09 | 0.32 | 0.16 | 0.19 | 0.19 | 0.00 | |
| Interest | 0.33 | 0.80 | 1.32 | 1.45 | 1.41 | 1.25 |
| Depreciation | 0.02 | 0.05 | 0.07 | 0.09 | 0.11 | 0.12 |
| Profit before tax | 1.04 | 1.57 | 1.49 | 1.21 | 1.45 | 1.77 |
| Tax % | 28.85% | 28.03% | 28.86% | 27.27% | 28.97% | |
| 0.73 | 1.14 | 1.06 | 0.88 | 1.03 | 1.27 | |
| EPS in Rs | 730.00 | 50.49 | 3.61 | 2.19 | 2.56 | 3.16 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -1% |
| TTM: | 94% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -3% |
| TTM: | 76% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -23% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 10% |
| Last Year: | 7% |
Balance Sheet
Figures in Rs. Crores
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|
| Equity Capital | 0.01 | 0.23 | 2.94 | 4.02 | 4.02 | 4.02 |
| Reserves | 0.93 | 3.80 | 2.15 | 10.62 | 11.66 | 12.23 |
| 3.02 | 6.14 | 10.18 | 5.73 | 9.46 | 10.50 | |
| 4.26 | 5.34 | 6.07 | 6.20 | 14.41 | 10.16 | |
| Total Liabilities | 8.22 | 15.51 | 21.34 | 26.57 | 39.55 | 36.91 |
| 0.09 | 0.34 | 2.22 | 2.51 | 2.51 | 2.61 | |
| CWIP | 0.00 | 0.00 | 1.79 | 6.13 | 8.61 | 11.84 |
| Investments | 0.00 | 0.04 | 0.14 | 0.20 | 0.34 | 0.41 |
| 8.13 | 15.13 | 17.19 | 17.73 | 28.09 | 22.05 | |
| Total Assets | 8.22 | 15.51 | 21.34 | 26.57 | 39.55 | 36.91 |
Cash Flows
Figures in Rs. Crores
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| -1.05 | -3.67 | 2.19 | 1.02 | 1.15 | |
| -0.05 | -0.34 | -4.82 | -4.76 | -2.70 | |
| 1.03 | 4.27 | 2.73 | 3.70 | 1.56 | |
| Net Cash Flow | -0.07 | 0.26 | 0.10 | -0.04 | 0.01 |
Ratios
Figures in Rs. Crores
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Debtor Days | 71.88 | 91.73 | 80.80 | 145.75 | 180.56 |
| Inventory Days | 7.23 | 3.41 | 31.18 | 4.10 | 0.75 |
| Days Payable | 45.43 | 38.52 | 47.22 | 57.45 | 102.56 |
| Cash Conversion Cycle | 33.68 | 56.62 | 64.76 | 92.39 | 78.76 |
| Working Capital Days | 22.20 | 33.07 | 17.16 | 71.71 | 29.89 |
| ROCE % | 33.55% | 22.09% | 14.93% | 12.57% |
Documents
Announcements
-
Statement of deviation(s) or variation(s) under Reg. 32
13 November 2025 - No deviation in IPO proceeds; Rs911.23L disclosed, Rs873.00L utilized, Rs0.38L unutilized (30 Sep 2025).
-
Outcome of Board Meeting
13 November 2025 - Approved unaudited half-year results ended 30 Sep 2025; utilized Rs873.00 lakhs of Rs911.23 lakhs.
-
Certificate under SEBI (Depositories and Participants) Regulations, 2018
19 October 2025 - Certificate under Reg 74(5) confirming demat/remat details for quarter ended 30 Sep 2025.
-
Change in Director(s)
9 October 2025 - Board appointed Santosh Palav (Non‑Executive Director) and Ravindra Salaskar (Whole‑time Director, KMP) effective 09 Oct 2025; Salaskar five-year term.
-
Appointment
3 October 2025 - AGM approved M/s H. Maheshwari & Associates as secretarial auditors for FY2025-26 to FY2029-30.
Business Overview:[1]
SPIIL is in the business of trading in Pharma API, Pharma Intermediates, Chemicals, Solvents, and other pharmaceutical products, used
for human and veterinary medicine